CD19 and graft versus host disease: Although incidence of grade 3–4 acute GvHD were comparable in both types of TCD-HCT (23.1% vs. 22.6%), this risk was higher than that reported with other methods of TCD (e.g., CD3-CD19- or TCRαβ-/CD19-).